Enough red tape! We want to cure MDS!
The MDS Clinical Research Consortium (MDS CRC) is currently conducting a clinical trial on myelodysplastic syndrome and we need your help.
Patients, help us cure MDS. Predicting Response to Your Myelodysplastic Syndrome (MDS) Treatment is currently running and we are seeking participants.
Click here to learn about our current trial focusing myelodysplastic syndrome and see if you may be eligible to participate and contribute to this incredibly important research.
The MDS Clinical Research Consortium (MDS CRC) is an alliance between six of the nation's leading institutions dedicated to studying MDS.
Formation of the alliance was inspired by Edward Parker Evans, who himself suffered from MDS. Mr. Evans recognized that there is a tremendous amount of "red tape" separating patients from new and more effective treatments in myelodysplastic syndrome and he wanted to dramatically speed up the process.
He envisioned that an elite clinical research consortium specifically for myelodysplastic syndrome would facilitate collaboration between leading institutions and researchers, speed up drug development, and minimize bureaucracy. Thus, through the Edward P. Evans Foundation, he funded the development of the MDS-CRC. The Consortium is the first of its kind and MDS-CRC investigators are leading unique, high-quality clinical and laboratory studies that are hoped will change the day-to-day care of people with MDS as soon as possible.
Everything we do in the CRC is designed to try to get answers to your most urgent questions as soon as possible: why does a drug work in myelodysplastic syndrome? Why does another drug not work? Why do some drugs work for some patients, but not for others? How can we make myelodysplastic syndrome drugs work better? Is there any way to prevent myelodysplastic syndrome?
Help us discover the answers to these and other questions by joining one of our MDS-CRC studies. Please watch this space for additional resources and helpful information about myelodysplastic syndrome.